Sermorelin & GHRP-2 Blend (10mg)

Sermorelin & GHRP-2 Blend

Sermorelin and GHRP-2 are synthetic peptides that, through different proposed biological pathways, may support the stimulation of growth hormone (GH) synthesis and release.

Sermorelin is a 29–amino acid peptide representing the active core fragment of endogenous growth hormone-releasing hormone (GHRH), which normally consists of 44 amino acids. It is considered the shortest functional analog of GHRH and is C-terminally amidated. Research by Clark et al. suggests that Sermorelin retains the ability to bind to GHRH receptors on pituitary somatotroph cells and activate them. These receptors are central to endogenous GH production, positioning Sermorelin as a GHRH mimetic.

GHRP-2 (growth hormone-releasing peptide-2), described by Berlanga-Acosta et al., is a fully synthetic hexapeptide derived from earlier growth hormone-releasing peptides and structurally related to modified enkephalins. Unlike opioid-active peptides, it is designed to preferentially act on ghrelin (growth hormone secretagogue) receptors rather than opioid receptors, thereby promoting GH release.

Because both compounds influence GH secretion through distinct receptor systems, they are classified as growth hormone secretagogues. Researchers suggest that engaging multiple pituitary pathways may produce complementary or potentially synergistic effects, although further investigation is needed.

---

Chemical Information

Alternative names

• Sermorelin: GRF 1-29 NH₂
• GHRP-2: Pralmorelin

Molecular formula

• Sermorelin: C149H246N44O42S
• GHRP-2: C45H55N9O6

Molecular weight

• Sermorelin: 93 g/mol
• GHRP-2: 97 g/mol

---

Research and Mechanisms

Pituitary signaling activity

Sermorelin primarily interacts with GHRH receptors on pituitary cells. Studies such as those by Culhane et al. describe this as a G-protein–coupled receptor process that increases intracellular cAMP via adenylate cyclase activation. This signaling cascade ultimately promotes GH synthesis and secretion, which can also contribute to downstream IGF-1 production in peripheral tissues.

GHRP-2, in contrast, targets GHSR-1a (ghrelin receptors), also expressed in the hypothalamus and pituitary. According to Yin et al., this receptor is a G-protein–coupled receptor that activates phospholipase C (PLC), generating IP₃ and DAG. These messengers increase intracellular calcium and activate protein kinase C (PKC), processes associated with GH release from somatotroph cells.

---

Effects on GH secretion

Evidence from Vittone et al. suggests Sermorelin may approximately double GH output in experimental settings, increasing both mean GH levels and integrated secretion over time, while not significantly altering pulse frequency or systemic IGF-1 in some measures. However, localized tissue-level effects of IGF-1 remain a proposed mechanism.

Khorram et al. report that Sermorelin’s strongest effect on GH release occurs within the first few hours of exposure, with corresponding increases in IGF-1 of roughly 25–30% observed in some studies.

For GHRP-2, research by Bowers et al. indicates a sustained stimulatory effect on GH secretion, with multi-fold increases in 24-hour GH output and a corresponding rise in IGF-1 levels under experimental conditions. This suggests a prolonged enhancement of pulsatile GH activity rather than a transient spike.

---

Potential effects on other tissues

Some studies, such as those by Chatelain et al., suggest that increased GH and IGF-1 signaling may influence Leydig cell activity, potentially affecting testosterone production through modulation of LH/hCG receptor expression. These mechanisms remain theoretical and primarily based on animal or in vitro models.

Other research (e.g., Granado et al.) suggests GHRP-2 may also interact with immune-related pathways in liver-associated cells, potentially reducing inflammatory markers in experimental endotoxemia models. This may involve receptor interactions on macrophage-like cells such as Kupffer cells.

---

Synergistic Potential

Experimental studies indicate that combining GHRH analogs like Sermorelin with GHRP-2 may amplify GH release more than either compound alone. Bowers et al. and Veldhuis et al. report significantly higher GH output when both receptor pathways are activated simultaneously, consistent with a dual-pathway stimulation model.

Similarly, small clinical observations (e.g., Sigalos et al.) suggest that combined administration may elevate IGF-1 more than monotherapy, though study design limitations prevent definitive conclusions.

Overall, the proposed rationale for combining Sermorelin with GHRP-2 is based on complementary receptor activation at the pituitary level, potentially enhancing pulsatile GH secretion in experimental contexts.

---

This blend is described as intended for research and laboratory use only.